Carmike Cinemas (Nasdaq: CKEC) reported earnings on Nov. 1. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Carmike Cinemas missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped significantly.

Margins shrank across the board.

Revenue details
Carmike Cinemas tallied revenue of $127.5 million. The seven analysts polled by S&P Capital IQ foresaw a top line of $130.9 million on the same basis. GAAP reported sales were 4.9% lower than the prior-year quarter's $134.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.13. The five earnings estimates compiled by S&P Capital IQ anticipated $0.20 per share. GAAP EPS of $0.01 for Q3 were 96% lower than the prior-year quarter's $0.24 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 19.0%, 80 basis points worse than the prior-year quarter. Operating margin was 7.9%, 250 basis points worse than the prior-year quarter. Net margin was 0.2%, 210 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $129.6 million. On the bottom line, the average EPS estimate is $0.23.

Next year's average estimate for revenue is $527.6 million. The average EPS estimate is $0.98.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 52 members out of 97 rating the stock outperform, and 45 members rating it underperform. Among 23 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 13 give Carmike Cinemas a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Carmike Cinemas is outperform, with an average price target of $20.06.